

Real-world Treatment Experience of Single-tablet Dolutegravir/Lamivudine in those Naïve to Treatment with Baseline Viral Loads ≥100,000 copies/mL the United States

P Benson¹, C Donovan², G Harper³, D Merrill², K Mycock³, A Oglesby,² J Patarroyo², <u>A Metzner²</u> ¹Be Well Medical Center, Berkley, MI, USA; ²ViiV Healthcare, Durham, NC, USA; ³Adelphi Real World, Bollington, Cheshire, UK

Key Takeaways

- TANDEM aimed to characterize real-world prescribing behaviors and treatment outcomes of DTG-based 2DR in the United States (US).
 - Here we describe demographics, clinical characteristics and outcomes of treatment naïve PLWH with high baseline VLs (≥100,000 copies/ mL) who initiated DTG/3TC.
- Out of the 16 PLWH with high baseline VLs, 13 experienced sustained virological suppression (<50 copies/mL) with no treatment discontinuations after a median follow-up time of >1 year on DTG/3TC.
- Data supports results from phase 3 clinical trials demonstrating DTG/3TC is an effective, well tolerated regimen when used in real-world settings in treatment-naïve PLWH with baseline VLs >100k, including >250k.

Introduction

- Treatment for people living with human immunodeficiency virus (HIV)-1 (PLWH) continues to advance with a two-drug regimen (2DR) approach [1].
- Dolutegravir/ lamivudine (DTG/3TC) is indicated as a 2DR for both treatment naïve and virally suppressed PLWH[2].
- This approach is supported by a strong recommendation (AI*) from the DHHS Clinical Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV among PLWH with baseline VLs <500,000 copies/mL[3].
- The GEMINI and STAT trials demonstrated similarly high efficacy in treatment naïve PLWH across baseline VL strata ≥100,000 and <100,000 copies/mL
- Though small in number, participants with baseline VLs \geq 500,000 copies/mL include 13 and 19 participants from GEMINI and STAT respectively [4-5].
- Here we describe outcomes of treatment-naïve PLWH initiated on DTG/3TC with baseline viral loads of ≥100,000 copies/mL from TANDEM (n=16 out of 126); primary results have been presented previously [6-7].

Methods

- TANDEM was a US-based, retrospective chart review. 24 sites abstracted clinical characteristic, treatment history, and post-initiation outcomes data from medical charts of PLWH who were initiated on DTG/3TC or DTG/RPV.
- Analyses were descriptive and no formal hypotheses were tested.
- Missing data were not imputed. Descriptive analyses were performed in IBM[®] SPSS[®] Data Collection Survey Reporter v7.5 software.
- Time to event outcomes were calculated using Kaplan-Meier estimators conducted in StataCorp, 2015. Stata statistical software: Release 16 (College Station, TX, StataCorp LP).

Inclusion Criteria

- ≥18 years old;
- Have a diagnosis of HIV-1 infection;
- Have a history of antiretroviral therapy (ART) consisting of the 2DR DTG/3TC or DTG/RPV as a single-tablet regimen (STR);
- DTG/3TC cohort:
 - Must have been initiated on or after 1st May 2019 and before 30th September 2020;
 - Upon initiation, PLWH must have been either treatment naïve [TN] to ART or virologically suppressed (i.e. stable switch [SS]) defined as having HIV-1 RNA <50 copies/mL, on a stable ART regimen for \geq 3 months upon DTG-based 2DR initiation.
- Have at least 6 months of clinical follow-up after initiation of DTG-based 2DR which could include time post-discontinuation of either regimen.


*Rating for Recommendations = Strong (A) / Rating of Evidence = Data from randomized controlled trials (I)

IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC

Results

- From an overall sample of 469 PLWH, 151 received DTG/RPV and 318 received DTG/3TC, of whom 126 were TN and 192 were SS (Figure 1).
- Of the TN population (n=126), 58 had known baseline VLs available at DTG/3TC initiation. 9 had values 100,000-250,000 copies/mL while 7 were >250,000 copies/mL. Of these 7, four had VLs ≥500,000 copies/mL
- Demographics of the sub-cohort of TN PLWH with baseline VLs \geq 100,000 copies/mL are described in Table 1
- Overall, the most common reasons for DTG/3TC initiation in those with baseline VLs 100,000–250k copies/mL were PLWH preference (n=2), convenience (n=2) and weight gain (n=2). For those with baseline VLs >250k copies/mL, PLWH preference (n=3), avoidance of long-term toxicities (n=2) and convenience (n=1) were most important (Figure 2).

Figure 1. TANDEM Study




n=151, 32.2% n=318, 67.8%					
	DTG/3TC TN n=126, 39.6%			100-250k copies/mL (n=9)	>250k copies/mL (n=7)
			Laboratory values prior to DTG/3TC initiation		
Abbreviations: $TN = Treatment$ naïve to ART upon DTG/3TC initiation; $SS = Virologically$ suppressed (i.e. stable switch) with HIV-RNA <50 copies/mL, on a stable ART regimen for \geq 3 months upon DTG/3TC initiation			Median HIV viral load, copies/mL(IQR)	192,000 (147,619, 215,000)	722,422 (278,000, 2,680,017)
Table 1. Baseline Demographics			Median CD4 cell count, cells/mm ³ (IQR)	312 (43.5, 584)	114 (29, 481)
	100-250k	>250k	Viral suppression status on DTG/3TC, n (%)	n=9	n=7
	copies/mL (n=9)	copies/mL (n=7)	Became virally suppressed ¹	8 (88.9)	6 (85.7)
Age (years)			No data available / Information unknown	1 (11.1)	1 (14.3)
Median (Interquartile range, (IQR))	34.0 (30.5, 46.5)	33.0 (26.0, 50.0)	Time to viral suppression from DTG/3TC initiat	ion, n n=8	n=6
Assigned Sex at Birth, n (%)			Median Weeks (IQR)	11.2 (6.2, 30.0)	20.6 (10.5, 32.4)
Male	7 (77.8)	7 (100.0)	Rebound status following viral suppression, n	(%) n=8	n=6
Current Gender Identity, n (%)			Remained virally suppressed	8 (100.0)	5 (83.3)
Cis-male	7 (77.8)	6 (85.7)	Rebounded ²	0 (0.0)	1 (16.7)
Cis-female	2 (22.2)	0 (0.0)	Time from viral suppression to rebound, n	n=0	n=1
Trans-female	0 (0.0)	1 (14.3)	Median Weeks (IQR)	-	18.1 (18.1, 18.1)
Race, n (%)			Ongoing DTG/3TC ³ , n (%)	9 (100.0)	7 (100.0)
White/Caucasian	4 (44.4)	4 (57.1)	Median time on DTG/3TC ongoing (years)	1.2 (0.8, 1.8)	1.0 (0.7, 1.1)
Black	4 (44.4)	2 (28.6)	Drug Resistance Testing Performed at	n=9	n=7
Mixed race	0 (0.0)	1 (14.3)	DTG/3TC initiation, n (%)		
Not specified	1 (11.1)	0 (0.0)	No resistance testing performed	3 (33.3)	5 (71.4)
Ethnicity, n (%)			Resistance testing performed; resistance	1 (11.1)	0 (0.0)
Hispanic / Latinx	4 (44.4)	2 (28.6)	detected ⁴		
Current Insurance Coverage, n (%)			Resistance testing performed; no resistance	4 (44.4)	2 (28.6)
Employer provided/ sponsored insurance	3 (33.3)	2 (28.6)	detected		
Privately arranged insurance	1 (11.1)	4 (57.1)	Information unknown	1 (11.1)	0 (0.0)
Medicaid	4 (44.4)	1 (14.3)	¹ Viral suppression defined as a HIV-1 viral load of <50 copies/mL ² Rebound defined as two consecutive viral load measurements of ≥200 copies/mL after viral suppression (<50 copies/mL). ³ At the time of data abstraction, excludes PLWH lost to follow-up or treatment status unknown. ⁴ Both NNRTI and PI resistance was detected in this N=1 PLWH, with detected mutations 'Not otherwise specified' for both types of resistance.		
AIDS Drug Assistance Program (ADAP)	1 (11.1)	0 (0.0)			

Acknowledgments: The authors would like to thank the study investigators across each of the 24 US-based sites for their contribution towards the study in abstracting the data from medical charts of PLWH who were initiated on DTG/3TC.

Funding: Adelphi Real World were paid consultants to ViiV Healthcare (study Sponsor) in connection with development of this publication.

Figure 2. HCP Reasons for Initiating DTG/3TC for High Baseline Viral Load





Clinical Characteristics & Virological Outcomes

term toxicities

• Clinical characteristics are described in **Table 2**.

• Baseline drug resistance testing was performed in 43.8% of PLWH with baseline VLs ≥100k copies/mL. Resistance-associated mutations were detected in 1 person (6.3%).

Table 2. Baseline Clinical Characteristics & Virologic Outcomes

References: 1. Waters, L. and Church, H., Curr. Opin. Infect. Dis., 2020; 33(1): 28-33. 2. van Wyk, J. et al., Clin. Infect. Dis. 2020;71(8):1920-1929. **3**. US Departments of Health and Human Services. *Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.* Accessed March 2, 2022. **4.** Cahn, P. et al., J. Aqcuir. Immune. Defic. Syndr. 2020;8(8):310-318. **5.** Rolle, C.P., et al., AIDS, 2021;35(12):1957-1965. **6.** Schneider, S. et al., IAS Conference 2022, Montreal; Poster # EPB147. 7. Blick, G. et al., AMCP Nexus Conference 2022, National Harbor, MD.

- 312 cells/mm³.

Desired Health Outcomes

Limitations

- population.

Conclusions



Presenting author: Aimee Metzner, PharmD, AAHIVP 410 Blackwell Street. Durham. North Carolina, 27701 aimee.a.metzner@viivhealthcare.com Phone: (+1) 727-200-0305



• For those with baseline VLs between 100–250k copies/mL, median CD4+ count was

• 8/9 PLWH became virally suppressed (HIV-1 viral load <50 copies/mL) while receiving DTG/3TC and 1 had missing data.

• For those with baseline VLs >250k, median CD4 count was 114 cells/mm³.

• 6/7 became virally suppressed while receiving DTG/3TC and 1 had missing data.

• Of these six, 1 experienced virological rebound yet remained on DTG/3TC.

• This 1 PLWH had no resistance testing performed at DTG/3TC initiation.

• Median time to viral suppression following DTG/3TC initiation was 11.2 and 20.6


weeks in the 100-250k and >250k sub-cohorts respectively.

• Treating physicians were asked in their opinion 'what was the primary reason for initiating DTG/3TC' and then if the 'desired health outcome(s) that motivated DTG/3TC use' had been achieved for each PLWH[†].

• The desired health outcome was achieved in 7/9 of PLWH with baseline VLs 100-250k copies/mL and 5/7 with baseline VLs >250k copies/mL (Figure 3).

• All PLWH with high baseline VLs (16/16) remained on DTG/3TC, at point of data abstraction, for a median duration of 1.2 and 1.0 years in the 100-250k and >250k sub-cohorts respectively.





Yes

Too soon to tell/ Unsuret

⁺'In your opinion, did their most recent DTG-based 2DR achieve the desired health outcome(s) that motivated its use? (e.g., treatment was simplified, intolerability ceased or avoided, drug-drug interactions (DDI) were avoided, exposure during pregnancy avoided, adherence improved, etc.)' [‡] For example, data not available in the medical records or insufficient follow-up to establish the treatment effect.

• The small sample size (n=16) may limit extrapolation of these results to a broader

• This was a retrospective chart review therefore data may be missing or incomplete.

• TANDEM captured treatment outcomes up to and including virological rebound only; thus, there is no knowledge of outcomes post-rebound in the 1 PLWH who rebounded.

• Data from TN Test and Treat (T&T) users of DTG/3TC observed in TANDEM are not included in this sub-cohort due to the lack of baseline VL. This population could have potentially contributed to the overall sub-cohort size.

• Findings from this T&T sub-cohort can be found in Poster 1279 at ID Week 2022.

• Outcomes were explored of a subset of PLWH in TANDEM who initiated onto DTG/3TC with high baseline VLs >100k.

 Out of the 16 PLWH with high baseline VLs, 13 experienced sustained virological suppression with no treatment discontinuations.

• TANDEM supports results from phase 3 clinical trials demonstrating DTG/3TC is an effective and well tolerated regimen when used in real-world settings in treatment-naïve PLWH with baseline VLs >100k, including >250k.



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.